These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 8301878

  • 1. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I, Kubota T, Fujimoto K, Sakamoto H, Hasegawa M, Furuta H, Yamaguchi N.
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract] [Full Text] [Related]

  • 2. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G, Pollock B, Voineskos G, Reed K, Coulter K.
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [Abstract] [Full Text] [Related]

  • 3. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, Gonzalez-Monclus E.
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [Abstract] [Full Text] [Related]

  • 4. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V, DeVane CL, Korpi ER, Venable D, Bigelow LB, Wyatt RJ, Kirch DG.
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [Abstract] [Full Text] [Related]

  • 5. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T, Marder SR, Mintz J.
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [Abstract] [Full Text] [Related]

  • 6. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
    Perry PJ, Miller DD, Arndt SV, Smith DA, Holman TL.
    J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
    [Abstract] [Full Text] [Related]

  • 7. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S.
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Beyond the therapeutic window: a case presentation.
    Schulz SC, Butterfield L, Garicano M, Narasimhachari N, Friedel RO.
    J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212
    [Abstract] [Full Text] [Related]

  • 16. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A, Segal Z, Yeret A, Ben-David M.
    Commun Psychopharmacol; 1980 May; 4(3):203-6. PubMed ID: 7226751
    [No Abstract] [Full Text] [Related]

  • 17. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM, Amorim P, Piketti ML, Bourdel MC, Poirier-Littré MF.
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.